Journey Medical Corp. (DERM), a commercial-stage pharmaceutical company that focuses on the treatment of dermatological conditions, is approaching a key regulatory milestone next month that should be closely monitored.
The company's investigational drug, DFD-29, proposed for the treatment of inflammatory lesions and erythema of rosacea in adults, is under FDA review, with a decision due on November 4, 2024.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.